|
MechanismIL-2R antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismCD138 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with MAB Designs Ltd.
0 Patents (Medical) associated with MAB Designs Ltd.
100 Deals associated with MAB Designs Ltd.
100 Translational Medicine associated with MAB Designs Ltd.